Where Purpose Meets Progress –  accelerating progress for Leiomyosarcoma research, through advancing collaborative priorities of the research community and the patient communities served by the NLMSF.”

This website is dedicated to Gilles Frydman and to all the contributors of the original Leiomyosarcoma.info website (listed here ) who provided a valuable compass to guide LMS patients/caregivers/families.
This Leiomyosarcoma research website is also dedicated to the heroes among us, the patients and their families, and the researchers who work tirelessly every day to better understand this rare and complicated sarcoma to advance treatment options and improve survivorship.

Leiomyosarcoma information

Unmet Medical Needs and Future Perspectives for Leiomyosarcoma Patients—A Position Paper from the National LeioMyoSarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN)

Principle Author: Bernd Kasper, MD, PhD
Professor, Univeritalsmedizin Mannheim
NLMSF - SPAEN Executive Committee / International LMS Research Roundtable Steering Committee
About Dr.Kasper

What Clinical Trials Are Needed for Treatment of Leiomyosarcoma?

Kasper 2022_Research Update


Rebecca Gladdy, MD PHD

About Dr. Gladdy


- A comprehensive Research Paper guided by Dr. Rebecca Gladdy,Sarcoma Research Clinician/Surgeon, Mt .Sinai Hospital, Toronto.  Esteemed member of the NLMSF-SPAEN  International LMS Research Roundtable.  This publication is yet another compass for the Roundtable focus workgroups: Lineage-defined leiomyosarcoma subtypes emerge years before diagnosis and determine patient survival https://www.nature.com/articles/s41467-021-24677-6

General sarcoma information

Scott Okuno, MD Professor of Oncology Mayo Clinic Rochester, MN

"We are glad that you have come to our Leiomyosarcoma Research website  (Leiomyosarcoma.info ) of the National LMS Foundation. We are continuously updating this website to provide information on advances in Leiomyosarcoma research as well as the numerous collaborations that are occurring. The NLMSF has additional resources about Leiomyosarcoma on the  NLMSF.org site. We are interested in your feedback as we continue to strive to improve sharing of Leiomyosarcoma information."

Dr Seth Pollack, MD Director of the Sarcoma Program at the Lurie Cancer Center ROBERT H. LURIE COMPREHENSIVE CANCER CENTER OF NORTHWESTERN UNIVERSITY

“ I love the NLMSF – I love the patient programs held – your signature support advocacy to collaborate with sarcoma centers. LMS is common enough to have had a specific focus initiative- and the NLMSF was many steps ahead of the curve,  to launch the LMS International Research Roundtable  - to support patients in this way, and focus on LMS-specific research and support in the research landscape. Annie and Mitch are such a good team for the LMS Roundtable. They compliment each other with their unique strengths in moving forward to help patients and giving a special spotlight to LMS in particular.”


Arun Singh, M.D. Associate Professor Sarcoma Service Division of Hematology-Oncology, U.C.L.A.

"The National Leiomyosarcoma Foundation is an important organization that strives to gather a critical mass of patients, scientists, patient advocates and physicians to learn more about this rare disease. Within the NLMSF,  the LMS Research Roundtable organizes cutting edge research in this area and strives to innovate the ways that this disease is treated."


"We recognized that to effectively study a rare cancer we had to assemble an outstanding international team from premier sarcoma centers,” said principal investigator Scott Schuetze, M.D. Ph.D .
The NLMSF is proud to have committed to a five year funding pledge of support for this LMS-specific research, and very pleased that Dr. Mitch Achee (LMS survivor and physician) was selected to be a member of the External Advisory Board for the SPORE.
He will lead the engagement of LMS patient advocate group for this initiative.
Annie Achee, NLMSF
"Paying it Forward to the LMS Community in partnership with the Research Community"

NLMSF proudly collaborates with these research-related organizations: